Semiquantitative testing of the stool samples: frequency of enterovirus infections with high and low viral load in the children who subsequently developed repeated positivity of multiple autoantibodies vs. matched control subjects who did not develop autoimmunity
| . | Case subjects . | Control subjects . |
|---|---|---|
| n | 27 | 53 |
| Enterovirus RNA-negative | 296 | 598 |
| Enterovirus RNA-positive, low-moderate quantity* | 18 (5.3) | 46 (6.6) |
| Enterovirus RNA-positive, high quantity* | 25 (7.4) | 48 (6.9) |
| Total | 339 | 692 |
| Enterovirus RNA-negative | 296 | 598 |
| New infection episode, low-moderate quantity* | 11 (3.4) | 31 (4.7) |
| New infection episode, high quantity* | 19 (5.9) | 34 (5.1) |
| Total† | 326 | 663 |
| . | Case subjects . | Control subjects . |
|---|---|---|
| n | 27 | 53 |
| Enterovirus RNA-negative | 296 | 598 |
| Enterovirus RNA-positive, low-moderate quantity* | 18 (5.3) | 46 (6.6) |
| Enterovirus RNA-positive, high quantity* | 25 (7.4) | 48 (6.9) |
| Total | 339 | 692 |
| Enterovirus RNA-negative | 296 | 598 |
| New infection episode, low-moderate quantity* | 11 (3.4) | 31 (4.7) |
| New infection episode, high quantity* | 19 (5.9) | 34 (5.1) |
| Total† | 326 | 663 |
Data are n or n (%).
*Negative, <100 copies/ml enterovirus RNA; low-moderate quantity, 100–9,999 copies/ml enterovirus RNA; high quantity, 310,000 copies/ml enterovirus RNA;
†Excluding consecutively positive samples that may have been part of the same infectious episode as in the previous positive sample.